The obesity therapeutics market has experienced extraordinary growth over the past several years, driven largely by the success of GLP-1 receptor agonists. What was once considered an emerging therapeutic area has become one of the fastest-growing segments in biopharmaceuticals, attracting significant investment and fueling a wave of innovation.
The question now is no longer whether the obesity market will continue to grow. Instead, the industry has reached a critical inflection point: What will define the next generation of obesity treatment? Will future therapies deliver greater weight loss, or will they redefine success by improving the broader spectrum of metabolic health?
For years, the conversation has centered on one metric: how much weight patients can lose with increasingly potent GLP-1 therapies. These medicines have fundamentally transformed obesity care, proving that substantial, sustained weight loss is achievable through pharmacologic intervention and changing expectations for both physicians and patients.
As clinicians gain more experience treating obesity, however, another reality has become increasingly apparent. Obesity is far more than a disease of excess body weight. It is a complex metabolic disorder that frequently coexists with type 2 diabetes, metabolic dysfunction-associated steatohepatitis (MASH), cardiovascular disease, and numerous other chronic conditions. While weight loss can substantially improve many obesity-related conditions, it may not fully address the underlying metabolic abnormalities or comorbidities present in every patient.
Consequently, the future of obesity treatment probably won't rely solely on stronger single drugs. Instead, it may involve carefully crafted combination therapies that aim at multiple, complementary metabolic pathways at once. This approach could enhance weight loss, glucose regulation, liver health, insulin sensitivity, and other factors essential for sustained metabolic well-being.
Beyond Weight Loss
GLP-1 therapies have set a new standard by delivering unprecedented weight reduction. Their success has also solidified obesity as a treatable chronic disease rather than one considered a lifestyle condition. Yet even the most effective GLP-1 therapies leave important clinical questions unanswered.
Not every patient responds equally. Many discontinue therapy because of tolerability or gastrointestinal side effects. Others regain weight after stopping the treatment. Perhaps the most important revelation is that substantial weight loss does not necessarily normalize every aspect of metabolic health.
Patients and physicians increasingly want therapies that can do more than reduce the number on the scale. They want treatments that improve insulin sensitivity, preserve lean muscle mass, reduce liver fat, enhance cardiovascular health, and address the broad spectrum of metabolic dysfunction associated with obesity.
This evolution in clinical expectations is driving a broader shift in research and development.
Obesity is a Metabolic Disease
For decades, obesity research focused primarily on reducing caloric intake and body weight.
Today, we recognize that obesity involves complex interactions among multiple organs and signaling pathways, including liver, pancreas, adipose tissue, gastrointestinal tract, skeletal muscle, and central nervous system.
These systems influence glucose metabolism, lipid regulation, inflammation, energy expenditure, and insulin sensitivity. Dysregulation across these interconnected pathways contributes not only to obesity itself but also to diseases such as type 2 diabetes and MASH.
Treating one pathway exceptionally well may still leave other drivers of disease untouched. The challenge is proving that a second mechanism changes the disease, beyond the number on the scale.
Why Combination Therapy Makes Sense
Combination therapy has transformed treatment in many therapeutic areas, from oncology and HIV to hypertension and diabetes. Rather than relying on a single mechanism, clinicians often combine complementary approaches to improve efficacy while reducing limitations associated with individual agents.
The same logic increasingly applies to obesity. This is already taking two forms: single-molecule multi-pathway agents and separate drug combinations. Single-molecule agents can offer simpler dosing and strong efficacy, although receptor activity is fixed once the biology is built into one molecule. Separate combinations bring more development burden, but they offer flexibility: Each component can be adjusted, stopped, or selected for a specific clinical problem.
Different metabolic pathways influence different aspects of disease biology. Pairing therapies with complementary mechanisms offers the potential to produce additive or even synergistic effects across multiple clinical outcomes.
Researchers are beginning to ask broader questions beyond how much additional weight people can lose. For example, can we preserve lean body mass during weight reduction? Or can we reduce liver fat and inflammation at the same time?
These are the types of questions that will increasingly shape future obesity drug development.
Emerging Evidence Supports a Broader Strategy
Recent preclinical research presented by MetaVia, the company of which I am the chief medical officer, at the American Diabetes Association (ADA) Scientific Sessions illustrates the promise of this approach.1-3
In separate studies, our team evaluated vanoglipel, a G protein-coupled receptor 119 agonist, in combination with metformin and with resmetirom, drugs for type 2 diabetes and MASH, respectively. Across these studies, the combinations demonstrated enhanced weight loss, improved glucose control, and better liver health compared with monotherapy.
While additional clinical research is needed, these findings provide a rationale for evaluating whether complementary mechanisms can produce broader metabolic benefits when combined.
Because obesity, type 2 diabetes, and MASH share important aspects of metabolic biology, therapeutic strategies that address these overlapping pathways may offer benefits across multiple obesity-related conditions.
Looking Ahead to More Personalized Treatment
Over the next five years, obesity treatment is likely to become increasingly personalized.
Rather than searching for a single "best" therapy, clinicians may have access to combinations tailored to an individual's metabolic profile, comorbidities, treatment goals, and disease stage.
Some patients may require therapies optimized for weight reduction. Others may benefit from combinations that prioritize glucose control, liver health, or preservation of lean mass. As our understanding of metabolic biology continues to evolve, treatment strategies will become more nuanced and more precise.
GLP-1 therapies have fundamentally reshaped obesity care and opened the door to a new era of innovation.
The next chapter will build on that success, not by replacing GLP-1s, but by complementing them with therapies that address the full complexity of metabolic disease.
- Fang WC, et al. 3102-LB: Safety, tolerability, pharmacokinetics, and pharmacodynamics of DA-1726, an oxyntomodulin analogue: Phase 1 higher-dose cohort results. Diabetes. 2026;75(Supplement_1):3102–LB.
- Chae Y, et al. 3043-LB: Synergistic hepatoprotective and weight-loss effects of vanoglipel and resmetirom combination therapy in a diet-induced obese, biopsy-confirmed mouse model of MASH. Diabetes. 2026;75(Supplement_1):3043–LB.
- Chae Y, et al. 2856-LB: Synergistic effects of vanoglipel and metformin on glycemic control and body weight reduction in a diet-induced obese mouse model. Diabetes. 2026;75(Supplement_1):2856–LB.
